JP2019505596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505596A5 JP2019505596A5 JP2018563379A JP2018563379A JP2019505596A5 JP 2019505596 A5 JP2019505596 A5 JP 2019505596A5 JP 2018563379 A JP2018563379 A JP 2018563379A JP 2018563379 A JP2018563379 A JP 2018563379A JP 2019505596 A5 JP2019505596 A5 JP 2019505596A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- adpr
- disease
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 70
- PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 241000701161 unidentified adenovirus Species 0.000 claims description 15
- 206010023332 keratitis Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 210000002345 respiratory system Anatomy 0.000 claims description 12
- 238000011200 topical administration Methods 0.000 claims description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- SMBQBQBNOXIFSF-UHFFFAOYSA-N dilithium Chemical class [Li][Li] SMBQBQBNOXIFSF-UHFFFAOYSA-N 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 206010006448 Bronchiolitis Diseases 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 201000008197 Laryngitis Diseases 0.000 claims description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 6
- 201000007100 Pharyngitis Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 6
- 229910052744 lithium Inorganic materials 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 206010044008 tonsillitis Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical group NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229960000724 cidofovir Drugs 0.000 claims description 4
- 229910017052 cobalt Inorganic materials 0.000 claims description 4
- 239000010941 cobalt Substances 0.000 claims description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 4
- 239000012738 dissolution medium Substances 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- 229910003002 lithium salt Inorganic materials 0.000 claims description 4
- 159000000002 lithium salts Chemical class 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 206010039083 rhinitis Diseases 0.000 claims description 4
- 201000009890 sinusitis Diseases 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000019155 Radiation injury Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims description 2
- 201000004813 Bronchopneumonia Diseases 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 206010011416 Croup infectious Diseases 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 241000792859 Enema Species 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010023335 Keratitis interstitial Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
- 201000010927 Mucositis Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 206010044302 Tracheitis Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 238000012387 aerosolization Methods 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000001879 copper Chemical class 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 201000010549 croup Diseases 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 229940095399 enema Drugs 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 201000006904 interstitial keratitis Diseases 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000008263 liquid aerosol Substances 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 238000002663 nebulization Methods 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 206010033072 otitis externa Diseases 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 claims description 2
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 claims description 2
- 201000003826 superficial keratitis Diseases 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims 6
- 238000007911 parenteral administration Methods 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 38
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021149881A JP7222042B2 (ja) | 2016-02-18 | 2021-09-15 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2023014497A JP7600282B2 (ja) | 2016-02-18 | 2023-02-02 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2024210859A JP2025032189A (ja) | 2016-02-18 | 2024-12-04 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296665P | 2016-02-18 | 2016-02-18 | |
| US62/296,665 | 2016-02-18 | ||
| US201662428721P | 2016-12-01 | 2016-12-01 | |
| US62/428,721 | 2016-12-01 | ||
| PCT/US2017/018253 WO2017143113A1 (en) | 2016-02-18 | 2017-02-17 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021149881A Division JP7222042B2 (ja) | 2016-02-18 | 2021-09-15 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505596A JP2019505596A (ja) | 2019-02-28 |
| JP2019505596A5 true JP2019505596A5 (https=) | 2020-04-02 |
| JP6946353B2 JP6946353B2 (ja) | 2021-10-06 |
Family
ID=58191671
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563379A Active JP6946353B2 (ja) | 2016-02-18 | 2017-02-17 | ５′−アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2021149881A Active JP7222042B2 (ja) | 2016-02-18 | 2021-09-15 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2023014497A Active JP7600282B2 (ja) | 2016-02-18 | 2023-02-02 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2024210859A Pending JP2025032189A (ja) | 2016-02-18 | 2024-12-04 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021149881A Active JP7222042B2 (ja) | 2016-02-18 | 2021-09-15 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2023014497A Active JP7600282B2 (ja) | 2016-02-18 | 2023-02-02 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2024210859A Pending JP2025032189A (ja) | 2016-02-18 | 2024-12-04 | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11110112B2 (https=) |
| EP (2) | EP3416654B1 (https=) |
| JP (4) | JP6946353B2 (https=) |
| KR (2) | KR102622656B1 (https=) |
| CN (2) | CN108601793B (https=) |
| AU (2) | AU2017219878B2 (https=) |
| BR (1) | BR112018016398A2 (https=) |
| DK (1) | DK3416654T3 (https=) |
| ES (1) | ES2900524T3 (https=) |
| HR (1) | HRP20211942T1 (https=) |
| HU (1) | HUE057052T2 (https=) |
| IL (2) | IL291574B2 (https=) |
| LT (1) | LT3416654T (https=) |
| PL (1) | PL3416654T3 (https=) |
| PT (1) | PT3416654T (https=) |
| WO (1) | WO2017143113A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102622656B1 (ko) | 2016-02-18 | 2024-01-10 | 인버사, 인크. | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 |
| WO2019191026A2 (en) * | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
| KR102789553B1 (ko) * | 2021-09-07 | 2025-04-03 | 주식회사 펄스인마이어스 | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 |
| EP4509133A4 (en) * | 2023-03-02 | 2026-03-25 | Pearlsinmires Co Ltd | ADP-RIBOSE BINDING PEPTIDE FOR CANCER PREVENTION OR TREATMENT, AND ADP-RIBOSE POLYTHERAPY |
| WO2026073064A1 (en) * | 2024-09-30 | 2026-04-02 | Invirsa, Inc. | 5'-adenosine diphosphate ribose (adpr) for use in improving visual acuity |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0618214A1 (en) | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Unsaturated phosphonate derivatives of purines and pyrimidines |
| JPH07247210A (ja) | 1994-03-09 | 1995-09-26 | Sunstar Inc | 口腔用組成物 |
| JP2001515916A (ja) * | 1997-09-11 | 2001-09-25 | オクシジェン，インコーポレイテッド | 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法 |
| WO2000050024A2 (en) | 1999-02-26 | 2000-08-31 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
| EP1192258A2 (en) | 1999-06-16 | 2002-04-03 | Icos Corporation | Human poly(adp-ribose) polymerase 2 materials and methods |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| EP1409503A1 (en) | 2001-07-25 | 2004-04-21 | Celltech R & D Limited | Non-natural carbon-linked nucleotides and dinucleotides |
| AU2003230952A1 (en) | 2002-05-21 | 2003-12-12 | Abbott Laboratories | Treatment of mucositis |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| US20050276762A1 (en) | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
| WO2006127987A2 (en) | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| EP1948215B1 (en) | 2005-11-14 | 2012-01-11 | Centre National De La Recherche Scientifique (Cnrs) | MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof |
| WO2008154129A1 (en) | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| US20110217262A1 (en) | 2010-03-05 | 2011-09-08 | Kornfield Julia A | Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability |
| JP2013526514A (ja) | 2010-05-10 | 2013-06-24 | ラディカル・セラピューティックス・インコーポレイテッド | リポ酸およびニトロキシド誘導体およびその使用 |
| KR101967938B1 (ko) | 2011-05-12 | 2019-04-10 | 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 | 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물 |
| US20160287622A1 (en) | 2013-11-18 | 2016-10-06 | Massachusetts Institute Of Technology | Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction |
| KR102622656B1 (ko) | 2016-02-18 | 2024-01-10 | 인버사, 인크. | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 |
| WO2019191026A2 (en) | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
-
2017
- 2017-02-17 KR KR1020187022959A patent/KR102622656B1/ko active Active
- 2017-02-17 CN CN201780011126.0A patent/CN108601793B/zh active Active
- 2017-02-17 WO PCT/US2017/018253 patent/WO2017143113A1/en not_active Ceased
- 2017-02-17 EP EP17708104.9A patent/EP3416654B1/en active Active
- 2017-02-17 EP EP21198288.9A patent/EP3978003A1/en not_active Withdrawn
- 2017-02-17 AU AU2017219878A patent/AU2017219878B2/en active Active
- 2017-02-17 DK DK17708104.9T patent/DK3416654T3/da active
- 2017-02-17 BR BR112018016398A patent/BR112018016398A2/pt not_active Application Discontinuation
- 2017-02-17 HR HRP20211942TT patent/HRP20211942T1/hr unknown
- 2017-02-17 KR KR1020237034890A patent/KR102883682B1/ko active Active
- 2017-02-17 PL PL17708104T patent/PL3416654T3/pl unknown
- 2017-02-17 CN CN202311353882.5A patent/CN117482102A/zh active Pending
- 2017-02-17 LT LTEPPCT/US2017/018253T patent/LT3416654T/lt unknown
- 2017-02-17 HU HUE17708104A patent/HUE057052T2/hu unknown
- 2017-02-17 US US15/999,269 patent/US11110112B2/en active Active
- 2017-02-17 PT PT177081049T patent/PT3416654T/pt unknown
- 2017-02-17 IL IL291574A patent/IL291574B2/en unknown
- 2017-02-17 ES ES17708104T patent/ES2900524T3/es active Active
- 2017-02-17 JP JP2018563379A patent/JP6946353B2/ja active Active
-
2018
- 2018-08-10 IL IL261095A patent/IL261095B/en unknown
-
2021
- 2021-08-03 US US17/392,578 patent/US11857561B2/en active Active
- 2021-09-15 JP JP2021149881A patent/JP7222042B2/ja active Active
-
2023
- 2023-02-02 JP JP2023014497A patent/JP7600282B2/ja active Active
- 2023-03-17 AU AU2023201678A patent/AU2023201678B2/en active Active
- 2023-11-07 US US18/503,967 patent/US12370209B2/en active Active
-
2024
- 2024-12-04 JP JP2024210859A patent/JP2025032189A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505596A5 (https=) | ||
| ES2675588T3 (es) | Dendrímero como aminoamidas que posee actividad de bloqueador de canal de sodio para el tratamiento del ojo seco y otras enfermedades mucosas | |
| JP7600282B2 (ja) | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 | |
| RU2015129062A (ru) | Соединения 3, 5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида | |
| JP2021519315A5 (https=) | ||
| JP2023071933A5 (https=) | ||
| ES2825700T3 (es) | Derivados de pirimidina sustituidos útiles en el tratamiento de enfermedades autoinmunitarias | |
| US20250092076A1 (en) | Dithiolsaccharide mucolytic agents and uses thereof | |
| RU2015129076A (ru) | Арилалкил- и арилоксиалкил-замещенные соединения, блокирующие эпителиальный натриевый канал | |
| US20110166149A1 (en) | Pteridine derivatives for treating respiratory disease | |
| JP2009500354A (ja) | 肺疾患を治療するためのｐ２ｙ６受容体アゴニスト | |
| US20240335410A1 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
| JPWO2019191026A5 (https=) | ||
| JP6871919B2 (ja) | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 | |
| JPWO2019236496A5 (https=) | ||
| JP2013001677A (ja) | 抗コリン作動薬を含む再発性多発軟骨炎を含む気管気管支軟化症の治療剤 | |
| WO2005041858A2 (ja) | ムチン産生抑制剤 |